Vir Biotechnology, Inc.
NASDAQ:VIRBiotechnology
-$0.25 today
- Market cap
- $1.57B
- Beta
- 1.64
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.00
Volume 2.15M
Average 1.76M
VIR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Vir Biotechnology, Inc.NASDAQ: VIR
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $108.92M fell 8.2% year over year, ahead of the -15.0% change in trailing-twelve-month research & development. Sequentially, it rose 23.3% from the prior quarter. Over 3 fiscal years it compounded at -3.0% a year.
Context
- Research & development amounted to 631.3% of revenue in FY2025, down 51.3 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -8.2% holds above the trailing-twelve-month pace of -15.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 432.8M USD
- Year-over-year change
- -14.6%
- 4-year CAGR
- -0.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 432.8M | -14.6% |
| FY2024 | 2024-12-31 | 506.5M | -12.6% |
| FY2023 | 2023-12-31 | 579.72M | +22.1% |
| FY2022 | 2022-12-31 | 474.65M | +5.9% |
| FY2021 | 2021-12-31 | 448.01M | — |
Research & Development vs competitors
How VIR compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -15.0% is the 7th highest of 10, against a peer median of -0.6%.
- Research & development amounts to 681.3% of revenue for VIR, versus a peer median of 70.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.66B USD | -23.6% | -1.7% | 105.3% | |
| LTM Jun 2026 | €2.18B EUR | -0.6% | +9.6% | 82.6% | |
| LTM Mar 2026 | $446.24M USD | -15.0% | -3.0% | 681.3% | |
| LTM Mar 2026 | $345.36M USD | -10.9% | -35.2% | 57.9% | |
| LTM Jun 2026 | $197.76M USD | +15.5% | -13.1% | 21.0% | |
| LTM Mar 2026 | $159.57M USD | +37.4% | +18.6% | — | |
| LTM Mar 2026 | $91.32M USD | -20.8% | -13.4% | 131.9% | |
| LTM Mar 2026 | €85.57M EUR | +12.6% | -6.7% | 54.7% | |
| LTM Mar 2026 | $64.86M USD | +10.1% | -2.5% | 91.2% | |
| LTM Mar 2026 | $20.4M USD | -57.1% | -33.1% | 10.7% | |
| Peer median (excluding VIR) | — | -0.6% | -6.7% | 70.2% | |
Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.1B | 1.62B | 86.18M | 74.21M | 68.56M |
| Cost of Revenue | 513.87M | 620.97M | 572.83M | 478.65M | 11.71M |
| Gross Profit | 581.54M | 994.83M | (486.65M) | (404.44M) | 56.85M |
| Gross Margin | 53.1% | 61.6% | -564.7% | -545.0% | 82.9% |
| Research & Development | 448.01M | 474.65M | 579.72M | 506.5M | 432.8M |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 92.07M |
| Operating Expenses | 160.79M | 161.76M | 197.66M | 182.73M | 524.87M |
| Depreciation & Amortization | 5.81M | 6.78M | 19.45M | 14.56M | 11.68M |
| EBITDA | 555.61M | 761.06M | (641.64M) | (508.91M) | (426.09M) |
| EBITDA Margin | 50.7% | 47.1% | -744.5% | -685.8% | -621.5% |
| Operating Income | 420.75M | 833.07M | (684.31M) | (587.17M) | (468.02M) |
| Operating Margin | 38.4% | 51.6% | -794.0% | -791.3% | -682.7% |
| Interest Income | 439K | 28.09M | 86.99M | 71.81M | 40.24M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 129.05M | (78.79M) | 56.11M | 64.06M | 30.25M |
| Income Before Tax | 549.8M | 754.28M | (628.19M) | (523.11M) | (437.77M) |
| Pre-Tax Margin | 50.2% | 46.7% | -728.9% | -704.9% | -638.6% |
| Income Tax Expense | 21.22M | 238.44M | (13.08M) | (1.15M) | 217K |
| Net Income | 528.58M | 515.84M | (615.06M) | (521.96M) | (437.99M) |
| Net Margin | 48.3% | 31.9% | -713.7% | -703.4% | -638.9% |
| EPS (Basic) | 4.07 | 3.89 | (4.59) | (3.83) | (3.16) |
| EPS (Diluted) | 3.96 | 3.83 | (4.59) | (3.83) | (3.16) |
| Weighted Avg Shares | 129.88M | 132.61M | 134.13M | 136.25M | 138.52M |
| Weighted Avg Shares (Diluted) | 133.44M | 134.81M | 134.13M | 136.25M | 138.52M |
Vir Biotechnology, Inc.
NASDAQ:VIR
Intrinsic Alpha fair value
Locked
Current Price
$9.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.